On Wednesday, in the course of current trade, Shares of SAGE Therapeutics Inc (NASDAQ:SAGE), dropped -5.22%, and is now trading at $ 82.18.
SAGE Therapeutics, declared top-line data from an exploratory clinical trial that indicate a statistically noteworthy improvement from baseline in depression in four women with postpartum depression (PPD) within 24 hours after administration of intravenous SAGE-547 (paired t-test p=0.001). During the SAGE-547 treatment period, all four patients rapidly achieved remission, as measured by the Hamilton Rating Scale for Depression (HAM-D). The patients had a mean HAM-D score of 26.5 at baseline and improved to a mean HAM-D score of 1.8 at the end of the 60-hour treatment period. All four patients also demonstrated consistent improvement as measured by the Clinical Global Impression-Improvement (CGI-I) scale. SAGE-547 was well-tolerated in all patients treated with no serious adverse events observed on therapy or during the 30-day follow-up period.
“Severe postpartum depression is a serious and debilitating form of major depressive disorder,” said Samantha Meltzer-Brody, M.D., Director of the Perinatal Psychiatry Program, University of North Carolina Center for Women’s Mood Disorders and Principal Investigator of the trial. “The signal of SAGE-547’s activity is highly encouraging for women and their families facing the devastating consequences of this condition. I look forward to ongoing to study this treatment approach in the placebo-controlled trial.”
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes novel medicines to treat life-threatening and rare central nervous system disorders. The companys lead product candidate comprises SAGE-547, an intravenous (IV) agent that is in Phase I/II clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE).
During an Afternoon trade, Shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN), climbed 0.12%, and is now trading at $ 16.04.
Supernus Pharmaceuticals, declared that it will webcast its Investor Day presentation on June 17, 2015.
During the meeting, members of Supernus’ senior administration team will provide a detailed discussion of the Company’s clinical programs, counting efficacy and safety results for accomplished trials of its two late stage clinical programs, plans for prospective clinical trials, and an assessment of their market opportunity. In addition, several key thought leaders will share their perspectives on the current treatment paradigms, unmet medical needs, and the Company’s clinical development programs.
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its marketed products comprise Oxtellar XR, an extended-release oxcarbazepine and Trokendi XR, an extended-release topiramate, which are neurology products used for the treatment of epilepsy.
Shares of Visteon Corp (NYSE:VC), during its Wednesday’s current trading session fell - 0.91%, and is now trading at $ 108.97.
Visteon Corp, declared that Sachin Lawande has been designated president and chief executive officer of Visteon, effective June 29, 2015, succeeding Timothy D. Leuliette. Lawande will also join Visteon’s Board of Directors.
Lawande is an accomplished automotive OEM electronics veteran with over a decade of global leadership experience in the industry. From 2005, Lawande held several leadership roles at Harman International Industries, most recently serving as president of the Infotainment Division, the company’s largest division with nearly $3 billion in annual sales. Preceding to joining Harman, Lawande held senior roles at QNX Software Systems and 3Com Corporation.
Visteon Corporation designs, engineers, and manufactures products for original equipment vehicle manufacturers worldwide. It operates in three segments: Climate, Electronics, and Other.
Finally, NCR Corporation (NYSE:NCR), gained 0.36% Wednesday, hitting its highest level.
NCR Corporation, declared that it has chosen interactive video technology from NCR Corporation (NCR) to deliver extended teller services to its customers in Lebanon. Bank Audi launched its first NCR Interactive Teller at its Novo Palladium branch in Bab Idriss, Beirut. Interactive Teller allows bank customers to conduct transactions with a live, remote teller over an ATM.
With NCR Interactive Teller, customers can perform banking transactions, manage their accounts, deposit and cash cheques, deposit and withdraw cash, pay bills, transfer money to a Bank Audi account, and get live assistance through video conferencing with personal tellers.
NCR Corporation, a technology company, provides solutions and services that enable businesses to connect, interact, and transact with their customers worldwide. The company operates through four segments: Financial Services, Retail Solutions, Hospitality, and Emerging Industries.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
